文献速递妇科生殖医学

单剂量甲氨蝶呤治疗异位妊娠时常规监测β-人绒毛膜促性腺激素

Routine β-Human Chorionic Gonadotropin Monitoring for Single-Dose Methotrexate Treatment in Ectopic Pregnancy.
PubMed 文献 · J Minim Invasive Gynecol · 2017-08-08

本研究为单中心回顾性研究,纳入2009年1月至2016年12月期间接受单剂量甲氨蝶呤(50 mg/m2)治疗的184例异位妊娠患者,评估一种不检测第4天β-hCG的替代监测方案预测需重复给药的效果。新方案在首日β-hCG<2000 mIU/mL的患者中预测需第二次给药的敏感度为100%、特异度为88.7%;首日β-hCG≥2000 mIU/mL时两种监测方案效率相同。结论认为新监测模型可为部分异位妊娠患者提供与Stovall方案相当的临床效率且费用和随访负担更小。

要点

  • 新监测方案不检测第4天β-hCG,以第1天至第7天β-hCG下降>50%定义单剂量成功。
  • 首日β-hCG<2000 mIU/mL者,新方案预测需第二次给药的敏感度100%、特异度88.7%。
  • 首日β-hCG≥2000 mIU/mL者,两种监测方案效率相同。

核心结论

  • 不检测第4天β-hCG的新监测模型可为部分异位妊娠患者提供与Stovall方案相当的临床效率,且费用和随访负担更小。

研究设计与样本

  • 单中心回顾性研究(加拿大工作组分类II-3),大学附属医院,纳入2009年1月至2016年12月接受甲氨蝶呤治疗的184例异位妊娠患者。
  • 干预为单剂量甲氨蝶呤50 mg/m2,必要时按Stovall方案每7天重复给药,输卵管破裂者行腹腔镜手术。

主要发现

  • 新方案在首日β-hCG<2000 mIU/mL患者中预测需第二次给药的敏感度为100%、特异度为88.7%。
  • 首日β-hCG≥2000 mIU/mL患者中,两种监测方案效率相同。

关键数值与推荐

  • 新监测方案定义单剂量成功为临床稳定患者第1天至第7天β-hCG水平下降>50%。
  • 单剂量甲氨蝶呤剂量为50 mg/m2。

临床怎么用

  • 作者认为不检测第4天β-hCG的新监测模型可为部分异位妊娠患者提供与Stovall方案相当的临床效率,且费用和随访负担更小。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: To evaluate an alternative monitoring protocol without day 4 β-human chorionic gonadotropin (β-hCG) measurement for predicting the need for a repeated methotrexate (MTX) dose in patients undergoing single-dose MTX therapy for ectopic pregnancy (EP). DESIGN: Single-center retrospective study (Canadian Task Force classification II-3). SETTING: University-affiliated hospital. PATIENTS: Included in the study were 184 EP patients treated with MTX between January 2009 and December 2016. INTERVENTIONS: Single-dose MTX treatment (50 mg/m2). MEASUREMENTS AND MAIN RESULTS: The patients were treated with repeated doses of MTX every 7 days, if necessary, according to Stovall's protocol, or with laparoscopic surgery in cases of tubal rupture. The success of a single-dose of MTX according to the alternative measure was defined as a >50% decrease in the β-hCG level between days 1 and 7 in clinically stable patients. The sensitivity, specificity, false-negative rate, false-positive rate, and attributable risk of this new monitoring measure were calculated and compared with the traditional regimen. The new protocol had a sensitivity and specificity of 100% and 88.7%, respectively, for predicting a required second dose in patients whose day 1 β-hCG levels were <2000 mIU/mL. For patients with day 1 β-hCG level ≥2000 mIU/mL, both monitoring regimens had the same efficiency. CONCLUSIONS: The new monitoring model without the day 4 β-hCG measurement may offer both patients and clinicians multiple options to monitor single-dose MTX therapy for selected EP patients, with a comparable clinical efficiency to Stovall's protocol and less expense and follow-up burden to patients.

来源:J Minim Invasive Gynecol,查看原文。版权归原作者所有。

引用

  1. Dai Y, Zhang G, Zhu L, et al. Routine β-Human Chorionic Gonadotropin Monitoring for Single-Dose Methotrexate Treatment in Ectopic Pregnancy. J Minim Invasive Gynecol. 2017. PMID: 28800968. doi:10.1016/j.jmig.2017.07.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。